Oncology Research最新文献

{"title":"Tyrosine kinase inhibitors in first-line treatment of advanced NSCLC with epidermal growth factor receptor mutations: Real-world data from Vietnam.","authors":"Khanh Toan Nguyen, Thi Huong Pham, VAN Lam Ngo, VAN Tuan Bui, VAN Nhat Nguyen, Thi Phuong Thao Nguyen, Thi Khanh Ha Nguyen, Thi Thuy VAN Nguyen","doi":"10.32604/or.2025.061905","DOIUrl":"10.32604/or.2025.061905","url":null,"abstract":"<p><strong>Aims: </strong>The study aimed to evaluate the effectiveness and adverse events of tyrosine kinase inhibitors (TKIs) in the first-line treatment of <i>advanced non</i>-<i>small cell lung cancer (NSCLC)</i> with epidermal growth factor receptor (EGFR) mutations.</p><p><strong>Methods: </strong>A retrospective study on advanced NSCLC patients with EGFR mutations treated with TKIs as a first-line therapy at Nghe An Oncology Hospital, Vietnam between January 2017 and August 2023. The primary endpoints included objective response rate, progression-free survival, and tolerability. The secondary endpoint was overall survival.</p><p><strong>Results: </strong>A total of 211 patients received first-line treatment with Erlotinib (n = 74), Gefitinib (n = 85), Afatinib (n = 34) or Osimertinib (n = 18). The overall response rate was 76.7%, with Osimertinib at 83.4%, Afatinib at 73.6%, Erlotinib at 77.1%, and Gefitinib at 76.5%. The median progression-free survival in the Gefitinib group was 12.2 months (95% CI: 11.1-13.2), 13.4 months (95% CI: 10.6-16.2) in the Erlotinib group, 18.4 months (95% CI: 10.1-26.8) in the Afatinib group and 25.3 months in the Osimertinib group (<i>p</i> = 0.001). The median overall survival was 21.8 months (95% Cl: 15.0-28.4) in the Gefitinib group, 30 months (95% Cl: 19.1-40.9) in the Erlotinib group (<i>p</i> = 0.154). Most drug-related adverse events were grade 1 or 2. Diarrhea was the most frequent adverse event in the Afatinib group at 44.1%; rash was most common in the Erlotinib group at 60.8%; paronychia (31.8%), and interstitial lung disease (3.5%) were most frequent in the Gefitinib group.</p><p><strong>Conclusion: </strong>The TKIs as first-line therapies for advanced NSCLC patients with EGFR mutated are highly effective, prolong survival, and are well tolerated.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"33 7","pages":"1667-1677"},"PeriodicalIF":2.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: LncRNA PCGEM1 facilitates cervical cancer progression via miR-642a-5p/KIF5B axis.","authors":"Yuanlin Liu, Yan Liu, Yan Wang, Qiang Wang, Yan Yan, Dandan Zhang, Huiqin Liu","doi":"10.32604/or.2024.056768","DOIUrl":"https://doi.org/10.32604/or.2024.056768","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.32604/or.2024.047454.].</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"33 6","pages":"1505"},"PeriodicalIF":2.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: Overexpression of the Long Noncoding RNA FOXD2-AS1 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma Through the miR-195/Akt/mTOR Axis.","authors":"","doi":"10.32604/or.2024.062048","DOIUrl":"https://doi.org/10.32604/or.2024.062048","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.3727/096504019X15656904013079.].</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"33 6","pages":"1509"},"PeriodicalIF":2.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cell cycle proteins: Linking the cell cycle to tumors.","authors":"Jie Zhong, Jue Liu, Xing Tang, Wenchao Zhou, Guangming Song, Yuhuan Zeng, Xiaodi Zhang, Jianbin Zhou, L U Cao, Qunfeng Zhang, Yukun Li","doi":"10.32604/or.2025.058760","DOIUrl":"10.32604/or.2025.058760","url":null,"abstract":"<p><p>The cell cycle is a tightly coupled series of events that enable cells to grow and proliferate. Cyclin-dependent kinases (CDKs) play crucial roles in the cell cycle by enabling cells to transition between different phases when they are activated. Cell cycle proteins enhance the activity of CDKs, while natural CDK inhibitors (CDKIs) suppress them. The cell cycle continues in cycles under normal conditions, but when conditions change, cells halt or terminate the cell cycle. Tumors are tissues that grow out of control, and the mechanisms of various types of tumors are different; however, almost all tumor cells share several common characteristics, including proliferation, prevention of apoptosis and genomic instability. Cellular division is essential in the progression of cancer. A key characteristic of cancer is the uncontrolled growth of tumor cells, which is due to the erratic behavior of several proteins during the cell cycle. Therefore, cell cycle regulators are considered attractive targets for the treatment of cancer. The present analysis highlights proteins that play a direct role in controlling the tumor cell cycle, such as CDKs, and provides a brief overview of checkpoint kinases. The present review also discusses how cell cycle proteins contribute to cancer and describes some of the antitumor drugs that are being researched.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"33 6","pages":"1335-1346"},"PeriodicalIF":2.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144634/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances in understanding the role of sex hormone receptors in urothelial cancer.","authors":"Mohammad Amin Elahi Najafi, Takuo Matsukawa, Hiroshi Miyamoto","doi":"10.32604/or.2025.062142","DOIUrl":"10.32604/or.2025.062142","url":null,"abstract":"<p><p>Sex hormones, including androgens and estrogens, are known to have widespread physiological actions beyond the reproductive system via binding to their cognitive receptors, members of the nuclear receptor superfamily that function as ligand-inducible transcription factors. Meanwhile, a growing body of evidence has indicated the involvement of androgen receptor, as well as estrogen receptors such as estrogen receptor-α and estrogen receptor-β, in the pathogenesis and growth of various types of malignancies, including urothelial cancer. Additionally, in bladder cancer, the activity of sex hormone receptors has been implicated in modulating sensitivity to conventional non-surgical therapy. These may clearly explain sex-related differences in the incidence and prognosis of bladder cancer. This article focuses on summarizing the recent progress on understanding the role of sex hormones and their receptors in urothelial tumorigenesis, urothelial cancer progression, and resistance to non-surgical therapy for bladder cancer. Specifically, potential downstream effectors of sex hormone receptors have been newly identified. Thus, most of previous and subsequent data have indicated that activation of the androgen receptor or estrogen receptor-β pathway is favorable for urothelial cancer, while conflicting data exist especially on estrogen receptor-α functions.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"33 6","pages":"1255-1270"},"PeriodicalIF":2.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the correlation and mechanism of natural killer cell cytotoxic sensitivity against gastric cancer.","authors":"Wenzhuo Yang, Haodong Chen, Zhilan Zhang, Zhiyong Xia, Yuanyuan Jin, Zhaoyong Yang","doi":"10.32604/or.2025.059426","DOIUrl":"10.32604/or.2025.059426","url":null,"abstract":"<p><strong>Background: </strong>Human natural killer (NK) cells have attracted widespread attention as a potential adoptive cell therapy (ACT). However, the therapeutic effects of NK cell infusion in patients with solid tumors are limited. There is an urgent need to explore a suitable new treatment plan to overcome weaknesses and support the superior therapeutic activity of NK cells.</p><p><strong>Methods: </strong>In this study, the mechanisms underlying the susceptibility of gastric cancer (GC) cell lines AGS, HGC-27, and NCI-N87 to NK cell-mediated cytotoxicity were explored.</p><p><strong>Results: </strong>Lactic dehydrogenase (LDH) release assays showed that all three GC cell lines were susceptible to the umbilical cord blood NK (UCB-NK) cells, and HGC-27 cells with high CD56 expression were the most sensitive to UCB-NK, followed by NCI-N87 and AGS. When the expression of CD56 in HGC-27 cells decreased, the lytic activity of NK cells in HGC-27 cells was abating. In addition, combining oxaliplatin with NK cells produced additive anti-tumor effects <i>in vitro</i>, which may have resulted from oxaliplatin-induced NK group 2 member D (NKG2DL) upregulation in GC cells. These results of cytotoxicity activity showed that inhibition of CD56 expression might suppress the sensitivity of GC cells to NK cell-mediated cytotoxicity, and upregulation of the expression of NKG2DL on the surface of GC cells by oxaliplatin could enhance the killing sensitivity of NK cells.</p><p><strong>Conclusion: </strong>Collectively, our study provides a deeper theoretical foundation and a better therapeutic strategy for NK cell immunotherapy in the treatment of human GC.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"33 6","pages":"1485-1494"},"PeriodicalIF":2.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gallic acid suppresses esophageal squamous cell carcinoma progression and enhances cisplatin chemosensitivity through IL-6/STAT3/Notch pathway.","authors":"Nuran Bedolla, Hao Wu, Linyu Liu, Xueting Liu, Yanli Ren","doi":"10.32604/or.2025.060151","DOIUrl":"10.32604/or.2025.060151","url":null,"abstract":"<p><strong>Background: </strong>Gallic acid (GA), a plant-derived polyphenol, possesses diverse biological functions such as reducing inflammation and against tumors. Currently, the influence of GA on the resistance of esophageal squamous cell carcinoma (ESCC) cells to cisplatin (DDP) is not well understood.</p><p><strong>Methods: </strong>Cell counting kit-8 assay examined how GA affected KYSE30 and TE-1 cell viability. 5-Ethynyl-2'-deoxyuridine and TdT-mediated dUTP Nick-End labeling staining detected cell proliferation and apoptosis. Clone formation assay, flow cytometry, Carboxyfluorescein diacetate succinimidyl ester fluorescent probes, and Transwell assay determined cell biological properties, and 2',7'-Dichlorofluorescin diacetate (DCFH-DA) fluorescent probes detected oxidative stress levels. Signal transducer and activator of transcription 3 (STAT3)/Notch pathway protein levels after GA and/or Interleukin-6 (IL-6) intervention were examined through Western blot. Furthermore, a model for subcutaneous graft tumors was established in nude mice.</p><p><strong>Results: </strong>GA exerted suppressive effects on cell proliferation, and caused apoptosis of KYSE30 and TE-1 cells. IL-6 intervention activated the STAT3/Notch pathway and promoted the malignant biological properties of ESCC cells. In contrast, GA attenuated the effects of IL-6, while STAT3 or Notch inhibitor further enhanced the effects of GA, suggesting that GA inhibited the IL-6/STAT3/Notch pathway. Not only that, GA promoted oxidative stress and enhanced cell sensitivity to DDP both <i>in vitro</i> and <i>in vivo</i>.</p><p><strong>Conclusion: </strong>GA suppresses the malignant progression of ESCC and enhances cell sensitivity to DDP by hindering the IL-6/STAT3/Notch pathway.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"33 6","pages":"1473-1484"},"PeriodicalIF":2.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is miR-10a a tumor suppressor that modulates proliferation and invasion in high-grade bladder cancer?","authors":"THAINá Rodrigues, PATRíCIA Candido, Feres Camargo Maluf, Poliana ROMãO, Carolina Mie Mioshi, Vanessa Ribeiro GUIMARãES, Juliana Alves DE Camargo, Karina Serafim DA Silva, Gabriel Arantes Dos Santos, Iran Amorim Silva, Katia Ramos Moreira Leite, William C Nahas, Sabrina T Reis, Ruan Pimenta, Nayara Izabel Viana","doi":"10.32604/or.2025.055306","DOIUrl":"10.32604/or.2025.055306","url":null,"abstract":"<p><strong>Objectives: </strong>Bladder Cancer (BC) is one of the most commonly diagnosed malignancies worldwide, with high rates of mortality and morbidity. It can be classified as non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC), with radical cystectomy being the treatment for MIBC, which significantly reduces quality of life. MicroRNAs (miRs) act as critical genetic regulators, with both oncogenic and tumor-suppressive roles. MiR-10a is described as a tumor suppressor in various neoplasms, but its role in BC is controversial. This study aims to assess the activity of miR-10a in cellular invasion and proliferation in two distinct BC cell lines.</p><p><strong>Methods: </strong>The study used high-grade T24 and low-grade RT4 bladder cell lines. Cells were transfected with miR-10a mimic or a non-targeting control. Transfection efficiency was validated by qPCR. Cell proliferation was cultured for 10-14 days. Cell migration and invasion were evaluated using Matrigel. All assays were conducted in triplicate.</p><p><strong>Results: </strong>The T24 cells transfected with miR-10a presented decreased cellular proliferation and invasion compared to the Scramble (<i>p</i> = 0.0481 and <i>p</i> < 0.0001, respectively). In the RT4 cell line, there was only a significant reduction in cellular proliferation after miR-10a transfection (<i>p</i> = 0.0029). <b>Conclusions:</b> Our findings suggest that miR-10a has a tumoral suppressor role in BC, demonstrating higher efficacy in high-grade cells.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"33 6","pages":"1377-1382"},"PeriodicalIF":2.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular insights into immune evasion in head and neck squamous cell carcinomas: Toward a promising treatment strategy.","authors":"Hyeon Ji Kim, Bo Kyung Joo, Jin-Seok Byun, DO-Yeon Kim","doi":"10.32604/or.2025.062207","DOIUrl":"10.32604/or.2025.062207","url":null,"abstract":"<p><p>Head and neck squamous cell carcinoma (HNSCC) is a highly aggressive and devastating disease arising primarily from the mucosal epithelium of the oral cavity, pharynx, and larynx. HNSCC ranks as the sixth most common cancer worldwide, carrying significant morbidity and mortality. HPV-positive HNSCC can be partially prevented with the FDA-approved HPV vaccine and generally exhibits a more favorable prognosis compared to HPV-negative cases. However, effective screening and treatment approaches remain elusive for HPV-negative HNSCC. While precancerous lesions may precede invasive cancer in certain situations, most patients present with advanced disease without prior indication of precancerous conditions. Despite robust immune cell infiltration in HNSCC tumors, the extent and composition of immune infiltration vary widely among patients, and these tumors often evade immune surveillance through diverse mechanisms. Given the heterogeneous nature of HNSCC influenced by anatomical location and etiological factors, precise identification of biomarkers and personalized treatment strategies are imperative. In this study, we aim to explore the possibility of establishing an effective treatment strategy to overcome obstacles to targeted treatment and enable long-term survival through detailed molecular characterization and immune profiling of HNSCC.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"33 6","pages":"1271-1282"},"PeriodicalIF":2.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status, hotspots, and trends in cancer prevention, screening, diagnosis, treatment, and rehabilitation: A bibliometric analysis.","authors":"Chuchu Zhang, Ying Liu, Zehui Chen, Y I Liu, Qiyuan Mao, G E Zhang, Hongsheng Lin, Jiabin Zheng, Haiyan Li","doi":"10.32604/or.2025.059290","DOIUrl":"10.32604/or.2025.059290","url":null,"abstract":"<p><strong>Objectives: </strong>Decades of clinical and fundamental research advancements in oncology have led to significant breakthroughs such as early screening, targeted therapies, and immunotherapy, contributing to reduced mortality rates in cancer patients. Despite these achievements, cancer continues to be a major public health challenge. This study employs bibliometric techniques to visually analyze the English literature on cancer prevention, screening, diagnosis, treatment, and rehabilitation.</p><p><strong>Methods: </strong>We systematically reviewed publications from 01 March 2014, to 01 March 2024, indexed in the Web of Science core collection. Tools such as VOSviewer Version 1.6.20 is characterized by its core idea of co-occurrence clustering. CiteSpace 6.3.R3 is distinguished by its powerful capabilities in bibliometric analysis, including co-citation analysis, co-occurrence analysis of keywords, author collaboration network analysis, and journal co-citation analysis, providing effective insights into research hotspots and detecting emerging trends. Bibliometrix version 3.0.3 offers rich visualization features, including collaboration network diagrams, citation distribution graphs, and keyword clouds. facilitated the analysis of the literature, helping to map out the current research landscape, identify pressing issues, and discern emerging trends, thus offering insights for future research directions.</p><p><strong>Results: </strong>The analysis revealed that major research hotspots include lung and breast cancer. Attention is predominantly concentrated on cancer treatment, subdivided into targeted therapy, immunotherapy, traditional Chinese medicine, and the development of new anticancer drugs. Significant terms identified in the study include immune checkpoint inhibitors, tumor microenvironment, and cancer stem cells.</p><p><strong>Conclusion: </strong>This bibliometric analysis highlights the evolving directions in oncology research, pinpointing nanotherapy, resistance to targeted therapies, and the integration of artificial intelligence as pivotal future research avenues in the prevention, screening, diagnosis, treatment, and rehabilitation of cancer.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"33 6","pages":"1437-1458"},"PeriodicalIF":2.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}